EA201991299A1 - Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов - Google Patents

Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов

Info

Publication number
EA201991299A1
EA201991299A1 EA201991299A EA201991299A EA201991299A1 EA 201991299 A1 EA201991299 A1 EA 201991299A1 EA 201991299 A EA201991299 A EA 201991299A EA 201991299 A EA201991299 A EA 201991299A EA 201991299 A1 EA201991299 A1 EA 201991299A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
active pharmaceutical
delivery
pharmaceutical ingredients
cyclodextrin complexes
Prior art date
Application number
EA201991299A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61656066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201991299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of EA201991299A1 publication Critical patent/EA201991299A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)

Abstract

Настоящее изобретение относится к офтальмологическим композициям, содержащим твердые комплексы активного фармацевтического ингредиента и циклодекстрина, к способу их получения и к их применению. Композиции могут включать комплекс активный лекарственный агент/циклодекстрин, по существу, растворенный в водном носителе глазных капель. Офтальмологическая композиция обычно находится в форме микросуспензии, включающей комплекс активного агента, имеющий диаметр менее примерно 100 мкм.
EA201991299A 2016-11-29 2017-11-29 Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов EA201991299A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427737P 2016-11-29 2016-11-29
PCT/IB2017/001659 WO2018100434A1 (en) 2016-11-29 2017-11-29 Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

Publications (1)

Publication Number Publication Date
EA201991299A1 true EA201991299A1 (ru) 2019-11-29

Family

ID=61656066

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991299A EA201991299A1 (ru) 2016-11-29 2017-11-29 Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов

Country Status (31)

Country Link
US (6) US20190343846A1 (ru)
EP (2) EP3548091B1 (ru)
JP (2) JP7138103B2 (ru)
KR (3) KR20240036731A (ru)
CN (2) CN110177576B (ru)
AR (2) AR110270A1 (ru)
AU (1) AU2017369971B2 (ru)
BR (1) BR112019011067A2 (ru)
CA (1) CA3045226A1 (ru)
CL (1) CL2019001447A1 (ru)
CO (1) CO2019005729A2 (ru)
CY (1) CY1124917T1 (ru)
DK (1) DK3548091T3 (ru)
EA (1) EA201991299A1 (ru)
ES (1) ES2903383T3 (ru)
HR (1) HRP20220046T1 (ru)
HU (1) HUE057221T2 (ru)
IL (2) IL266964B1 (ru)
LT (1) LT3548091T (ru)
MA (1) MA46997B1 (ru)
MD (1) MD3548091T2 (ru)
MX (1) MX2019006221A (ru)
PH (1) PH12019550088A1 (ru)
PL (1) PL3548091T3 (ru)
PT (1) PT3548091T (ru)
RS (1) RS62845B1 (ru)
SI (1) SI3548091T1 (ru)
TW (2) TWI773706B (ru)
UA (1) UA124774C2 (ru)
WO (1) WO2018100434A1 (ru)
ZA (1) ZA201903307B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220046T1 (hr) * 2016-11-29 2022-04-15 Oculis SA Priprema čvrstih kompleksa ciklodekstrina za uporabu oftalmološki aktivnih farmaceutskih sastojka
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
CN110051859B (zh) * 2019-06-06 2020-06-12 鲁南制药集团股份有限公司 一种阿昔替尼环糊精包合物
US20220354869A1 (en) * 2019-07-01 2022-11-10 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
TWI756547B (zh) * 2019-07-15 2022-03-01 高雄榮民總醫院 奈米眼藥水及其製造方法
EP4171507A1 (en) * 2020-06-30 2023-05-03 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
WO2022158893A2 (ko) * 2021-01-21 2022-07-28 주식회사태준제약 점안 조성물
US20220233564A1 (en) * 2021-01-25 2022-07-28 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2023132947A1 (en) * 2022-01-05 2023-07-13 The Regents Of The University Of California Closo-dodecaiododecaborate complexes and methods of use for same
WO2023148231A1 (en) 2022-02-02 2023-08-10 Oculis SA Multidose ophthalmic compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
MXPA03004241A (es) * 2000-11-15 2004-12-03 Chandavarkar Mohan A Preparaciones farmaceuticas que comprenden corticosteroides y agentes antiinfecciosos.
WO2004069280A1 (en) 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
MXPA05008913A (es) * 2003-02-21 2005-10-05 Sun Pharmaceutical Ind Ltd Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20140163080A1 (en) * 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
EP2662094B1 (en) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
SI2887923T1 (sl) * 2012-08-24 2023-09-29 Sun Pharmaceutical Industries Limited Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
HRP20220046T1 (hr) * 2016-11-29 2022-04-15 Oculis SA Priprema čvrstih kompleksa ciklodekstrina za uporabu oftalmološki aktivnih farmaceutskih sastojka

Also Published As

Publication number Publication date
MA46997B1 (fr) 2022-01-31
US11491240B2 (en) 2022-11-08
KR20240036731A (ko) 2024-03-20
RS62845B1 (sr) 2022-02-28
PH12019550088A1 (en) 2020-06-15
US20190343846A1 (en) 2019-11-14
KR20230025939A (ko) 2023-02-23
IL266964B1 (en) 2024-02-01
AU2017369971B2 (en) 2023-06-01
ES2903383T3 (es) 2022-04-01
CL2019001447A1 (es) 2019-08-09
MA46997A (fr) 2019-10-09
JP7455917B2 (ja) 2024-03-26
US20230037486A1 (en) 2023-02-09
CN110177576A (zh) 2019-08-27
IL266964A (en) 2019-07-31
US20180147297A1 (en) 2018-05-31
LT3548091T (lt) 2022-02-10
MX2019006221A (es) 2019-10-07
PL3548091T3 (pl) 2022-03-28
EP4194011A1 (en) 2023-06-14
AU2017369971A1 (en) 2019-06-13
HRP20220046T1 (hr) 2022-04-15
TWI773706B (zh) 2022-08-11
KR20190091308A (ko) 2019-08-05
CN117018220A (zh) 2023-11-10
US20240091377A1 (en) 2024-03-21
TW201825100A (zh) 2018-07-16
UA124774C2 (uk) 2021-11-17
US20220008555A1 (en) 2022-01-13
CO2019005729A2 (es) 2019-08-30
CY1124917T1 (el) 2023-01-05
CA3045226A1 (en) 2018-06-07
DK3548091T3 (da) 2022-01-17
BR112019011067A2 (pt) 2019-12-17
HUE057221T2 (hu) 2022-04-28
JP2019535798A (ja) 2019-12-12
SI3548091T1 (sl) 2022-04-29
TWI810167B (zh) 2023-08-01
TW201818943A (zh) 2018-06-01
EP3548091B1 (en) 2021-12-01
PT3548091T (pt) 2022-01-21
WO2018100434A1 (en) 2018-06-07
US11135311B2 (en) 2021-10-05
MD3548091T2 (ro) 2022-03-31
AR110270A1 (es) 2019-03-13
EP3548091A1 (en) 2019-10-09
ZA201903307B (en) 2020-09-30
KR102525438B1 (ko) 2023-04-26
CN110177576B (zh) 2023-08-11
AR110269A1 (es) 2019-03-13
JP2022172291A (ja) 2022-11-15
JP7138103B2 (ja) 2022-09-15
IL310360A (en) 2024-03-01
US20230042785A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX2021004707A (es) Nuevos compuestos antihelminticos.
NZ767295A (en) Liquid inhalation formulation comprising rpl554
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
MX2020001356A (es) Composiciones farmaceuticas.
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
EA201992816A1 (ru) Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения
EA202191936A1 (ru) Липиды для доставки липидных наночастиц активных агентов
IN2014MU03782A (ru)
EA201991190A1 (ru) Фармацевтический комплексный препарат, содержащий амлодипин, лозартан и розувастатин
TH142795A (th) วิธีการผลิตสูตรส่วนผสมยาด็อกซี่ซัยคลิน (DoxycyclineHyclate)สำหรับละลายน้ำ
TH170460A (th) "องค์ประกอบเภสัชภัณฑ์สำหรับการให้ทางปากซึ่งประกอบรวมด้วยแทกเซน"
TH132221A (th) สิ่งเตรียมทางเภสัชกรรมสำหรับใช้ทางผิวหนัง